Fas/Fas配体在结直肠腺癌发生和免疫逃避中的作用  

THE ROLE OF FAS/FAS LIGAND IN TUMORIGENESIS AND IMMUNE ESCAPE IN COLON ADENOCARCINOMA

作　　者：肖秀丽[1] 赵东晖[1] 龙汉安[1] 马跃荣[1] 唐学清[1] 程显魁[1] 魏于全[2] 

机构地区：[1]泸州医学院病理学教研室,四川泸州646000 [2]四川大学华西医院肿瘤生物治疗中心

出　　处：《泸州医学院学报》2006年第4期298-301,共4页Journal of Luzhou Medical College

基　　金：四川省教育厅重点科研资助项目(编号99164)

摘　　要：目的:探讨Fas、FasL(Fas配体)在结直肠腺癌发生和免疫逃避中的作用。方法:采用Fas、FasL免疫组织化学染色和TUNEL法细胞凋亡染色双重标记法。对50例结直肠腺癌、44例大肠腺瘤、9例正常结肠组织及24例结直肠腺癌伴淋巴结转移癌进行Fas和FasL的检测。对50例结肠癌再用TUNEL法,检测不同FasL表达区结直肠癌细胞的凋亡情况。结果:①Fas在不同结肠组织中的表达规律是:结直肠腺癌中表达最低,其次是结肠腺瘤,表达水平最高的是正常结肠组织。FasL在不同结肠组织中的表达规律与Fas正好相反,结直肠腺癌组织中表达最高,其次是结肠腺瘤,正常结肠组织中几乎不表达FasL。②Fas、FasL的表达与结直肠腺癌患者的年龄、性别无关(P>0.05),与Dukes’分期、分化程度、有无淋巴结转移有关(P<0.05)。③在同一结直肠腺癌组织切片中,FasL表达不均匀:FasL表达阳性区(n=45)结直肠癌细胞的凋亡率(5.013%))比FasL阴性区(n=5)(2.815%)高(P<0.05)。④在24例结直肠腺癌淋巴结转移癌组织中,FasL均强阳性表达。结论:Fas/FasL系统在结直肠腺癌发生和免疫逃避中起重要的作用。Objective ：To investigate the role of Fas/Fas ligand （FasL） in tumorigenesis and immune escape in colon adenocareinoma. Methods：Double-labelling in situ including immunohistochemistry staining of Fas,FasL and TUNEL assay of apoptosis cell was adopted.Fas and FasL were measured by immunohistochemistry in 50 colon adenocarcinomas, 44 colon adenomas, 9 normal colon tissues and 24 lymph node metastases of colon adenocarcinoma.Then in different FasL expression regions, the apoptosis cells were detected by TUNEL. Results： （1） The expression rate of Fas was the lowest in colon adenocarcinoma tissue. It was the lower than that in colon adenomas, while it was the highest in normal tissue. Compared with Fas, FasL was highest in colon adenocarcinoma and the lowest in normal tissue. The FasL in colon adenomas was higher than that in normal tassue. （2） Expression of Fas/FasL was not correlated with age and gender of patients（P〉0.05）, but it was correlated with Duke＇s stage, tumor differentiation and lymph node metastasis. （3）In the same tumor tissue, FasL expression adenocarcinoma.Conclusion：Fas/FasL plays an important role in tumorigenesis and immune escape.

关 键 词：肿瘤 结肠 CD95 FAS配体 双重标记法 

分 类 号：R735.35[医药卫生—肿瘤]